Reverse genetic platform for inactivated and live-attenuated influenza vaccine

Jung, Eun Ju; Lee, Kwang Hee; Seong, Baik Lin

doi:10.3858/emm.2010.42.2.013

Cited by 22 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A bias of memory over naïve T cells is also evident in the Peyer's patches, the mucosalassociated lymphoid tissue that drains the gut (14). The abundance of memory T cells in the NALTs is supported by our observation that only memory CD8 + T cells can infiltrate these structures and do so only in response to local inflammation.…”

Section: Discussionsupporting

confidence: 64%

Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells

Pizzolla

Wang

Groom

et al. 2017

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The lymphoid tissue that drains the upper respiratory tract represents an important induction site for cytotoxic T lymphocyte (CTL) immunity to airborne pathogens and intranasal vaccines. Here, we investigated the role of the nasal-associated lymphoid tissues (NALTs), which are mucosal-associated lymphoid organs embedded in the submucosa of the nasal passage, in the initial priming and recall expansion of CD8+ T cells following an upper respiratory tract infection with a pathogenic influenza virus and immunization with a live attenuated influenza virus vaccine. Whereas NALTs served as the induction site for the recall expansion of memory CD8+ T cells following influenza virus infection or vaccination, they failed to support activation of naïve CD8+ T cells. Strikingly, NALTs, unlike other lymphoid tissues, were not routinely surveyed during the steady state by circulating T cells. The selective recruitment of memory T cells into these lymphoid structures occurred in response to infection-induced elevation of the chemokine CXCL10, which attracted CXCR3+ memory CD8+ T cells. These results have significant implications for intranasal vaccines, which deliver antigen to mucosal-associated lymphoid tissue and aim to elicit protective CTL-mediated immunity.

show abstract

Section: Discussionsupporting

confidence: 64%

Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells

Pizzolla

Wang

Groom

et al. 2017

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…The reassortant H5N1 vaccine was generated by a reverse genetics approach, as previously described [19]. Briefly, HA and neuraminidase (NA) genes of A/Chicken/Korea/ES/2003 (H5N1) virus (clade 2.5) were synthesized and cloned into the pHW2000 vector.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Single Dose of a Bivalent Vaccine Containing Inactivated Newcastle Disease Virus and Reassortant Highly Pathogenic Avian Influenza H5N1 Virus against Lethal HPAI and NDV Infection in Chickens

et al. 2013

View full text Add to dashboard Cite

Highly pathogenic avian influenza (HPAI) and Newcastle disease (ND) are 2 devastating diseases of poultry, which cause great economic losses to the poultry industry. In the present study, we developed a bivalent vaccine containing antigens of inactivated ND and reassortant HPAI H5N1 viruses as a candidate poultry vaccine, and we evaluated its immunogenicity and protective efficacy in specific pathogen-free chickens. The 6∶2 reassortant H5N1 vaccine strain containing the surface genes of the A/Chicken/Korea/ES/2003(H5N1) virus was successfully generated by reverse genetics. A polybasic cleavage site of the hemagglutinin segment was replaced by a monobasic cleavage site. We characterized the reverse genetics-derived reassortant HPAI H5N1 clade 2.5 vaccine strain by evaluating its growth kinetics in eggs, minimum effective dose in chickens, and cross-clade immunogenicity against HPAI clade 1 and 2. The bivalent vaccine was prepared by emulsifying inactivated ND (La Sota strain) and reassortant HPAI viruses with Montanide ISA 70 adjuvant. A single immunization with this vaccine induced high levels of hemagglutination-inhibiting antibody titers and protected chickens against a lethal challenge with the wild-type HPAI and ND viruses. Our results demonstrate that the bivalent, inactivated vaccine developed in this study is a promising approach for the control of both HPAI H5N1 and ND viral infections.

show abstract

“…2). Currently, the RG system of cold-adapted LAIV donor strains has been successfully established and is used in almost all vaccine constructs including pandemic vaccines [11,73]. The technique has been recently extended to generate a novel alternative cold-adapted LAIV [74], as an alternative to the classical repeated passage at lower temperatures, allowing the conversion of a wild type virus into a genetically homologous live attenuated vaccine strain.…”

Section: Live Attenuated Influenza Vaccinementioning

confidence: 99%

Principles underlying rational design of live attenuated influenza vaccines

Jang

Seong

2012

Clin Exp Vaccine Res

View full text Add to dashboard Cite

Despite recent innovative advances in molecular virology and the developments of vaccines, influenza virus remains a serious burden for human health. Vaccination has been considered a primary countermeasure for prevention of influenza infection. Live attenuated influenza vaccines (LAIVs) are particularly attracting attention as an effective strategy due to several advantages over inactivated vaccines. Cold-adaptation, as a classical means for attenuating viral virulence, has been successfully used for generating safe and effective donor strains of LAIVs against seasonal epidemics and occasional pandemics. Recently, the advent of reverse genetics technique expedited a variety of rational strategies to broaden the pool of LAIVs. Considering the breadth of antigenic diversity of influenza virus, the pool of LAIVs is likely to equip us with better options for controlling influenza pandemics. With a brief reflection on classical attenuating strategies used at the initial stage of development of LAIVs, especially on the principles underlying the development of cold-adapted LAIVs, we further discuss and outline other attenuation strategies especially with respect to the rationales for attenuation, and their practicality for mass production. Finally, we propose important considerations for a rational vaccine design, which will provide us with practical guidelines for improving the safety and effectiveness of LAIVs.

show abstract

Reverse genetic platform for inactivated and live-attenuated influenza vaccine

Cited by 22 publications

References 19 publications

Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells

Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells

Efficacy of Single Dose of a Bivalent Vaccine Containing Inactivated Newcastle Disease Virus and Reassortant Highly Pathogenic Avian Influenza H5N1 Virus against Lethal HPAI and NDV Infection in Chickens

Principles underlying rational design of live attenuated influenza vaccines

Contact Info

Product

Resources

About